Bruce E. Johnson

TL;DR: It is shown that whereas wild-type EGFR and the L858R mutant require dimerization for activation and oncogenic transformation, the exon 19 deletion, exon 20 insertion, and L8 58R/T790M EGFR mutants do not requireDimerization, and this implies that different EGfr mutants show differential requirements for dimerized and that disruption of dimerizations may be among the antitumor mechanisms of cetuximab.

TL;DR: Results support the previous finding that a subset of pulmonary carcinoid tumors are responsive to chemotherapy, and treatment regimens showing efficacy include octreotide-based therapies.

TL;DR: Comparing data on the clinical presentation and clinical courses of patients with Stage IIIB and IV BAC with data on other types of NSCLC shows that the incidence of bronchioloalveolar carcinoma of the lung appears to be rising.

TL;DR: A Phase II study was designed to evaluate VX‐710 in combination with doxorubicin and vincristine in patients with sensitive, recurrent small cell lung cancer (SCLC).

TL;DR: 88% of EFGR-mutant NSCLC patients who progressed on first-line TKI continued therapy beyond RECIST-PD, which is not the single determining factor for terminating TKI in EGFR-mutants NSCLCs, and additional radiographically defined progression criteria are needed.